SCDAA 41st Annual National Convention Program Booklet | Page 10

FRIDAY, SEPTEMBER 27, 2013 12:30 p.m.– 1:30 p.m. PLENARY SESSION IV………………………………………...Grand F-H INNOVATIVE TREATMENT AS WE SEARCH FOR A CURE
Moderator: Kim Smith-Whitley, MD and Andrea Williams

12:30 p.m. - 1:00 p.m. 1:00 p.m. - 1:30 p.m. 1:30 p.m. – 1:45 p.m. 1:45 p.m. – 3:15 p.m.

“New Advancements in Stem Cell Research” ............Donald Kohn, MD “Mast Cell Activation and Pain”................................Kalpna Gupta, PhD BREAK……………………………………………………………...Grand D SIMULTANEOUS SESSIONS II Oral Presentation of Selected Abstracts A. COMMUNITY BASED PROGRAMS…...……………………..Maryland
Moderator: Mark Goodwin, JD, MSW

1:45 pm. – 2:00 pm. 2:00 pm. – 2:15 pm. 2:15 pm. – 2:30 pm. 2:30 pm. – 2:45 pm.

Waiting for Learning: Basis for Educational Interaction Design in Waiting Areas..………………….............…..Zeina Leong, M.Ed., PhD With Sickle Cell Disease, Hydroxyurea and You ………………..…………...Betty Watts Carrington, BSN,RN, MS, EdD Virtual Mentor Program for Young Adults with Sickle Cell Disease Transitioning from Pediatric to Adult.....………...…Trevor Thompson 1st National Organizing Workshop of Sickle cell CBO’s .......................................................…...…..Mark Goodwin, JD, MSW B. PATIENT CARE II…...………………………….………………Delaware
Moderator: Kleber Fertrin, MD, PhD

1:45 pm. – 2:00 pm.

2:00 pm. – 2:15 pm.

2:15 pm. – 2:30 pm. 2:30 pm. – 2:45 pm.

2:45 pm. – 3:00 pm.

Educating Patients and Physicians on Hematopoietic Cell Transplantation as a Viable Treatment Option for Sickle Cell Disease………………………………..………….Naynesh Kamani, MD The Effectiveness of a Nurse Practitioner Chronic Pain Service on Healthcare Utilization by Patients with Sickle Cell Disease ………………………………..……….………….…Nneka Okoye, MSN Provider Perspective on Integrative Therapies for Pediatric Sickle Cell Related Pain- A Case Study Approach……….Caitlin Neri, MD, MPH Competing Dilemmas: Patient and Caregiver Perspectives on Pain, Opioid Management and Addiction among Sickle Cell Disease Patients with and without Extremely High Hospital Use.…..Daniel Weisberg, MD (c), Shan-Estelle Brown, PhD Monocyte Shift to a Non-Classical CD14DIM/CD16+ Phenotype Correlates with Fetal Hemoglobin Levels in Sickle Cell Anemia Patients Treated with Hyd ????????????????-????????????5??A?((